{"gene":"SSX2","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":1995,"finding":"SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain, identifying SSX2 as encoding a putative transcriptional repressor. The SYT-SSX2 fusion results from the t(X;18)(p11.2;q11.2) chromosomal translocation in synovial sarcoma.","method":"Sequence analysis of cloned fusion transcripts from synovial sarcoma specimens","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — original cloning and sequence characterization, foundational paper with 411 citations","pmids":["7539744"],"is_preprint":false},{"year":2002,"finding":"SSX2 interacts directly with two novel proteins: RAB3IP (human homologue of a Ras-like GTPase interactor) and SSX2IP (a novel nuclear protein). Both interactions occur via the N-terminal moiety of SSX2. Coexpression of SSX2 with RAB3IP relocates RAB3IP from the cytoplasm to the nucleus, and SSX2IP colocalizes with SSX2 in the nucleus.","method":"Yeast two-hybrid screen, GST pull-down assays (in vitro direct interaction), immunofluorescence of transfected cells, deletion mutant analysis","journal":"Genes, chromosomes & cancer","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal yeast two-hybrid plus GST pulldown reconstitution plus localization experiments with deletion mapping","pmids":["12007189"],"is_preprint":false},{"year":2006,"finding":"The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with it, independent of canonical Wnt signaling. Depletion of SYT-SSX2 in primary synovial sarcoma cells results in loss of nuclear beta-catenin and decreased beta-catenin signaling activity.","method":"Co-immunoprecipitation, subcellular fractionation, reporter assays, siRNA knockdown in primary synovial sarcoma cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, functional reporter assays, and loss-of-function in primary tumor cells with defined phenotypic readout","pmids":["16462762"],"is_preprint":false},{"year":2006,"finding":"SYT-SSX1 interacts preferentially with the transcriptional repressor Snail, while SYT-SSX2 interacts preferentially with Slug. Both fusion proteins prevent their respective repressors from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription.","method":"Coimmunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — Co-IP, ChIP, and functional reporter assays provide multiple orthogonal methods","pmids":["16849535"],"is_preprint":false},{"year":2006,"finding":"The SS18-SSX2 fusion protein functions as a transcriptional 'activator-repressor' that deregulates downstream target genes (including IGF2 and CD44) through epigenetic mechanisms, affecting histone modifications at CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region. SS18 moiety is associated with the SWI/SNF complex (coactivator) while SSX moiety is associated with the polycomb complex (corepressor), and both activities are retained in the fusion.","method":"Conditional expression system, cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal epigenomic methods (ChIP, bisulfite sequencing) with conditional expression system","pmids":["17018603"],"is_preprint":false},{"year":2007,"finding":"SYT-SSX2 remodels the cytoskeleton by activating the Eph/ephrin signaling pathway, inducing cell elongation, neurite-like extensions, and cell repulsion. SYT-SSX2 also independently stabilizes the microtubule network through accumulation of detyrosinated Glu tubulin. Blockade of EphB2 signaling reverses the aberrant cytoskeletal phenotype.","method":"Retroviral transduction, immunofluorescence, EphB2 signaling blockade rescue experiments, western blotting for Glu tubulin, nocodazole resistance assay, immunohistochemistry of synovial sarcoma tissues","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — multiple methods including genetic rescue (EphB2 blockade), confirmed in primary tumor tissue","pmids":["17686994"],"is_preprint":false},{"year":2009,"finding":"SYT-SSX2 interacts with the polycomb repressive complex and causes destabilization of the polycomb subunit Bmi1, resulting in impaired polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes.","method":"Co-immunoprecipitation, western blotting for H2A ubiquitination, RT-PCR for polycomb target gene reactivation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP with functional epigenetic readout (H2A ubiquitination) from a single lab","pmids":["19337376"],"is_preprint":false},{"year":2011,"finding":"SYT-SSX2 reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells by directly occupying and activating neural-specific genes while suppressing normal myogenic and adipogenic differentiation programs. SYT-SSX2 directly targets and upregulates FGFR2, and FGFR2 knockdown abrogates growth and attenuates the neural phenotype of both mesenchymal stem cells and synovial sarcoma cells.","method":"Retroviral transduction, genome-wide ChIP analysis, siRNA knockdown of FGFR2, differentiation assays, gene expression profiling","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP-based genome-wide occupancy, validated with loss-of-function rescue experiments in multiple cell types","pmids":["21996728"],"is_preprint":false},{"year":2012,"finding":"SS18-SSX2 increases BCL2 expression but represses other anti-apoptotic genes MCL1 and BCL2A1 by directly suppressing their expression via binding through ATF2 to the CRE in the promoters of these genes and recruiting TLE1/Groucho corepressor.","method":"ChIP, promoter reporter assays, co-immunoprecipitation, siRNA knockdown, in vitro and in vivo pharmacological studies with ABT-263","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct promoter binding, reporter assays, and identification of corepressor (TLE1) recruitment","pmids":["22797074"],"is_preprint":false},{"year":2012,"finding":"SYT-SSX2 is recruited genome-wide predominantly to polycomb-modified chromatin sites enriched with H3K27me3. Activated genes show SYT-SSX2/H3K27me3 sites within their body or near TSS, while downregulated genes are characterized by SYT-SSX2/H3K27me3 at long-range positions or by activation marks within the gene body.","method":"Genome-wide ChIP-seq, expression profiling, hierarchical clustering of epigenetic marks","journal":"BMC genomics","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP-seq with integrated expression analysis providing mechanistic insight into recruitment","pmids":["22594313"],"is_preprint":false},{"year":2014,"finding":"SSX2 is a chromatin-associated protein that binds double-stranded DNA in a sequence non-specific manner and antagonizes BMI1 and EZH2 polycomb group body formation, derepressing PcG target genes and negatively regulating H3K27me3 levels in melanoma cells. SSX2 antagonizes PcG function through an indirect mechanism without directly affecting overall PcG complex composition.","method":"Chromatin fractionation, DNA binding assays (EMSA/pulldown), immunofluorescence for PcG body formation, ChIP for H3K27me3, gene expression analysis after SSX2 knockdown/overexpression","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vitro DNA binding, ChIP, and functional gene derepression assays","pmids":["25249625"],"is_preprint":false},{"year":2014,"finding":"Ectopic SSX2 expression induces DNA damage, replication stress, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and a late apoptotic response in melanoma and breast cancer cells. Knockdown of SSX2 in melanoma cell lines reduces tumor cell growth, demonstrating SSX2 supports melanoma cell proliferation.","method":"Stable transfection/overexpression, flow cytometry for DNA content, immunofluorescence for γH2AX (DNA damage marker), β-galactosidase senescence assay, siRNA knockdown with proliferation assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple phenotypic readouts from single lab, overexpression and knockdown both performed","pmids":["25363656"],"is_preprint":false},{"year":2016,"finding":"SSX2 knockdown in prostate cancer cells results in epithelial morphology, increased cell proliferation, increased expression of genes involved in focal adhesion, decreased anchorage-independent growth, increased invasion, and increased tumorigenicity in vivo, indicating SSX2 regulates focal adhesion-related processes rather than driving EMT.","method":"siRNA knockdown, overexpression, morphological analysis, gene expression profiling, invasion assays, in vivo tumorigenicity assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 — knockdown and overexpression with defined cellular phenotypes and in vivo validation, single lab","pmids":["27276714"],"is_preprint":false},{"year":2019,"finding":"The Mediator complex is essential for SSX2-induced senescence; knockdown of MED1, MED4, and MED14 subunits perturbs SSX2-induced senescence development. This effect is specific to SSX2-induced senescence, as MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence.","method":"Functional genetic screen (RNAi library), siRNA validation knockdown experiments, β-galactosidase senescence assay, immunostaining of melanoma tumors vs. benign nevi, RNA-seq analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide genetic screen with validation experiments, specificity controls with other senescence inducers","pmids":["31695025"],"is_preprint":false},{"year":2021,"finding":"SSX2 induces the formation of a novel type of intranuclear lamin bodies containing both A and B type lamins but no other nuclear lamina components. This effect is dependent on S-phase progression and is independent of known SSX2 interactions with polycomb proteins and the Mediator complex.","method":"Immunofluorescence in multiple breast epithelial cell line models, cell cycle synchronization experiments, co-immunoprecipitation to test polycomb/Mediator involvement","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, immunofluorescence-based localization with cell cycle dependency established, no direct biochemical reconstitution","pmids":["34808373"],"is_preprint":false},{"year":2007,"finding":"SSX2 expression in prostate cancer cell lines can be induced by treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine, indicating that SSX2 expression is regulated by DNA methylation. Normal prostate epithelial cells do not show SSX2 induction under the same treatment.","method":"RT-PCR after 5-aza-2'-deoxycytidine treatment in cancer cell lines vs. normal cell line","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological demethylation experiment with appropriate normal cell control establishing epigenetic regulation","pmids":["17929270"],"is_preprint":false},{"year":2009,"finding":"SSX2 contains a C-terminal nuclear localization signal (NLS) that is required for its nuclear targeting. When expressed in Pichia pastoris, SSX2 containing the NLS accumulates in the endoplasmic reticulum in misfolded form rather than translocating to the nucleus, whereas deletion of the NLS allows correct folding and secretion.","method":"Indirect immunofluorescence of SSX2 and NLS-deletion mutant expressed in yeast, secretion assays, protein folding analysis","journal":"Applied microbiology and biotechnology","confidence":"Low","confidence_rationale":"Tier 3 — NLS function inferred from yeast expression system, not directly validated in mammalian cells","pmids":["19826807"],"is_preprint":false},{"year":2012,"finding":"SSX2 overexpression in MCF-7 breast cancer cells suppresses ERα and E-cadherin expression, promotes cell invasion in vitro and in vivo, and differentially regulates a set of proteins identified by comparative proteomics.","method":"Stable transfection, MTT assay, flow cytometry, transwell invasion assay, in vivo tumorigenicity assay, 2D-gel comparative proteomics","journal":"International journal of oncology","confidence":"Low","confidence_rationale":"Tier 3 — single lab overexpression study with phenotypic readouts but limited mechanistic pathway placement","pmids":["22344619"],"is_preprint":false},{"year":2018,"finding":"RAB3IP interacts with SSX2 and co-expression of RAB3IP and SSX2 is correlated in gastric cancer; RAB3IP promotes an invasive phenotype and is associated with epithelial-mesenchymal transition markers.","method":"Co-immunoprecipitation, western blotting, invasion assays in gastric cancer cell lines, expression correlation analysis","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP confirming prior yeast two-hybrid finding, phenotypic studies without direct mechanistic pathway placement for SSX2","pmids":["30005870"],"is_preprint":false}],"current_model":"SSX2 is a nuclear chromatin-associated protein that binds double-stranded DNA non-specifically, functions as a transcriptional repressor through its KRAB-homology domain, antagonizes polycomb repressive complex activity (destabilizing Bmi1, reducing H3K27me3, and derepressing PcG target genes), and when fused to SYT (as SS18-SSX2) acts as an aberrant transcriptional activator-repressor that recruits beta-catenin to the nucleus, interacts with Slug to derepress E-cadherin, binds ATF2/TLE1 to repress MCL1/BCL2A1, activates ephrin/EphB2 signaling to remodel the cytoskeleton, and genome-wide targets H3K27me3-marked polycomb chromatin to reprogram mesenchymal stem cell gene expression networks toward neural lineage commitment."},"narrative":{"teleology":[{"year":1995,"claim":"Identification of SSX2 as a KRAB-domain-containing putative transcriptional repressor fused to SYT in the synovial sarcoma t(X;18) translocation established the gene's basic domain architecture and disease relevance.","evidence":"Cloning and sequence analysis of fusion transcripts from synovial sarcoma specimens","pmids":["7539744"],"confidence":"High","gaps":["No direct evidence of transcriptional repression activity at this stage","KRAB domain homology does not confirm functional equivalence to canonical KRAB repressors"]},{"year":2002,"claim":"Discovery of RAB3IP and SSX2IP as direct N-terminal interaction partners of SSX2, with SSX2 capable of relocalizing RAB3IP to the nucleus, revealed SSX2's capacity to remodel protein subcellular localization.","evidence":"Yeast two-hybrid screen, GST pull-down, immunofluorescence, deletion mapping in transfected cells","pmids":["12007189"],"confidence":"High","gaps":["Physiological relevance of RAB3IP nuclear relocalization unknown","Endogenous complex formation not demonstrated"]},{"year":2006,"claim":"Multiple studies established that the SS18-SSX2 fusion protein functions as a dual activator-repressor by coupling SWI/SNF coactivation (SS18 moiety) with PcG corepression (SSX2 moiety), deregulating targets including IGF2 and CD44 through epigenetic mechanisms, while also recruiting β-catenin to the nucleus and sequestering Slug to derepress E-cadherin.","evidence":"Conditional expression with microarray profiling, ChIP for histone modifications, bisulfite sequencing, Co-IP, reporter assays, and siRNA knockdown in primary synovial sarcoma cells","pmids":["17018603","16462762","16849535"],"confidence":"High","gaps":["How SSX2 moiety directly engages PcG complexes biochemically was not resolved","Whether β-catenin and Slug interactions are direct or mediated through SS18 was unclear"]},{"year":2007,"claim":"SS18-SSX2 was shown to activate Eph/ephrin signaling to remodel the cytoskeleton and stabilize microtubules, and separately SSX2 expression was found to be silenced by DNA methylation in normal tissues.","evidence":"EphB2 signaling blockade rescue experiments with immunofluorescence and nocodazole resistance; RT-PCR after 5-aza-2'-deoxycytidine treatment","pmids":["17686994","17929270"],"confidence":"High","gaps":["Direct transcriptional target linking SS18-SSX2 to EphB2 upregulation not identified","Methylation-based silencing not mapped to specific CpG islands"]},{"year":2009,"claim":"The SSX2 portion of SS18-SSX2 was shown to destabilize the PcG subunit Bmi1 and impair H2A ubiquitination, providing a mechanism for PcG target gene reactivation, while a C-terminal NLS was identified as necessary for nuclear targeting.","evidence":"Co-IP, H2A ubiquitination western blotting, RT-PCR for PcG target reactivation; NLS deletion mutant analysis in yeast","pmids":["19337376","19826807"],"confidence":"Medium","gaps":["Bmi1 destabilization mechanism (proteasomal vs. transcriptional) not defined","NLS function validated only in yeast, not mammalian cells"]},{"year":2011,"claim":"Genome-wide ChIP analysis revealed that SS18-SSX2 directly occupies and activates neural-specific genes while suppressing myogenic programs in mesenchymal stem cells, with FGFR2 identified as a critical direct target whose knockdown abrogates sarcoma cell growth.","evidence":"Genome-wide ChIP, retroviral transduction of mesenchymal stem cells, FGFR2 siRNA knockdown with differentiation and growth assays","pmids":["21996728"],"confidence":"High","gaps":["Whether FGFR2 activation is sufficient for lineage reprogramming not tested","Cell-of-origin for synovial sarcoma in vivo not established by this study"]},{"year":2012,"claim":"ChIP-seq demonstrated that SS18-SSX2 is recruited genome-wide to H3K27me3-marked polycomb chromatin, with gene activation correlating to proximal occupancy and repression to distal occupancy or ATF2/TLE1 corepressor recruitment at specific promoters (MCL1, BCL2A1).","evidence":"Genome-wide ChIP-seq with integrated expression profiling; ChIP and reporter assays at MCL1/BCL2A1 promoters with TLE1 Co-IP","pmids":["22594313","22797074"],"confidence":"High","gaps":["Whether SS18-SSX2 directly contacts H3K27me3 or is recruited via adaptor proteins remains unresolved","Structural basis of ATF2/TLE1 interaction not determined"]},{"year":2014,"claim":"Wild-type SSX2 was established as a chromatin-associated, sequence-nonspecific DNA-binding protein that antagonizes PcG body formation and H3K27me3 levels through an indirect mechanism, and whose ectopic expression induces DNA damage, replication stress, and p53-dependent senescence.","evidence":"EMSA/DNA pulldown, ChIP for H3K27me3, immunofluorescence for PcG bodies; flow cytometry, γH2AX immunofluorescence, β-galactosidase senescence assay with knockdown controls","pmids":["25249625","25363656"],"confidence":"High","gaps":["Molecular mechanism by which SSX2 disrupts PcG bodies without altering complex composition is unknown","Whether DNA damage is a direct consequence of chromatin binding or an indirect effect not resolved"]},{"year":2019,"claim":"A functional genetic screen identified the Mediator complex (MED1, MED4, MED14) as specifically required for SSX2-induced senescence, distinguishing SSX2's senescence pathway from oncogene- or drug-induced senescence.","evidence":"RNAi library screen with siRNA validation, specificity controls against B-Raf and Epirubicin senescence, RNA-seq","pmids":["31695025"],"confidence":"Medium","gaps":["Whether SSX2 directly contacts Mediator subunits or acts through transcriptional intermediaries unknown","How Mediator engagement relates to PcG antagonism not clarified"]},{"year":2021,"claim":"SSX2 was found to induce novel intranuclear lamin A/B bodies in an S-phase-dependent manner, independent of its known PcG and Mediator interactions, revealing a previously unrecognized effect on nuclear architecture.","evidence":"Immunofluorescence in breast epithelial cell lines, cell cycle synchronization, Co-IP to exclude PcG/Mediator involvement","pmids":["34808373"],"confidence":"Medium","gaps":["Functional consequence of lamin body formation not determined","Whether lamin body formation is linked to DNA damage or replication stress phenotypes not tested","Biochemical reconstitution of SSX2-lamin interaction not performed"]},{"year":null,"claim":"The molecular mechanism by which SSX2 disrupts PcG body formation without altering complex composition, the structural basis of its sequence-nonspecific DNA binding, and how its chromatin remodeling, Mediator-dependent senescence, and lamin body formation activities are integrated remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of SSX2 bound to DNA or chromatin","No reconstituted system defining minimal domains for PcG antagonism","Relationship between lamin body formation, replication stress, and senescence unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,10]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,10,14,16]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,6,9,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,7,8]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[11,13]}],"complexes":[],"partners":["SSX2IP","RAB3IP","BMI1","CTNNB1","SNAI2","ATF2","TLE1"],"other_free_text":[]},"mechanistic_narrative":"SSX2 is a nuclear chromatin-associated protein that functions as a transcriptional repressor and antagonist of polycomb group (PcG) repressive complexes. Its N-terminal KRAB-homology domain mediates transcriptional repression, while the full-length protein binds double-stranded DNA in a sequence-nonspecific manner, destabilizes PcG body formation (including Bmi1 and EZH2), reduces H3K27me3 levels, and derepresses PcG target genes [PMID:7539744, PMID:25249625]. SSX2 interacts with SSX2IP and RAB3IP through its N-terminal region, induces DNA damage and replication stress leading to Mediator-dependent cellular senescence, and promotes formation of intranuclear lamin bodies during S-phase [PMID:12007189, PMID:25363656, PMID:31695025, PMID:34808373]. When fused to SS18 via the t(X;18) translocation in synovial sarcoma, the SS18-SSX2 oncoprotein is recruited genome-wide to H3K27me3-marked polycomb chromatin, where it reprograms mesenchymal stem cell differentiation toward neural lineage by coupling SWI/SNF coactivator and PcG corepressor activities, recruits β-catenin to the nucleus, sequesters Slug to derepress E-cadherin, and activates Eph/ephrin signaling to remodel the cytoskeleton [PMID:22594313, PMID:21996728, PMID:16462762, PMID:16849535, PMID:17686994]."},"prefetch_data":{"uniprot":{"accession":"Q16385","full_name":"Protein SSX2","aliases":["Cancer/testis antigen 5.2","CT5.2","Synovial sarcoma, X breakpoint 2","Tumor antigen HOM-MEL-40"],"length_aa":188,"mass_kda":21.6,"function":"Could act as a modulator of transcription","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q16385/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SSX2"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SSX2","total_profiled":1310},"omim":[{"mim_id":"612409","title":"RNA-BINDING MOTIF PROTEIN 14; RBM14","url":"https://www.omim.org/entry/612409"},{"mim_id":"608690","title":"SSX2-INTERACTING PROTEIN; SSX2IP","url":"https://www.omim.org/entry/608690"},{"mim_id":"608686","title":"RAB3A-INTERACTING PROTEIN; RAB3IP","url":"https://www.omim.org/entry/608686"},{"mim_id":"606473","title":"SS18-LIKE GENE 2; SS18L2","url":"https://www.omim.org/entry/606473"},{"mim_id":"600192","title":"SS18 SUBUNIT OF BAF CHROMATIN REMODELING COMPLEX; SS18","url":"https://www.omim.org/entry/600192"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nucleoli","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"testis","ntpm":15.6}],"url":"https://www.proteinatlas.org/search/SSX2"},"hgnc":{"alias_symbol":["HOM-MEL-40","HD21","MGC3884","MGC15364","MGC119055","CT5.2a"],"prev_symbol":["SSX"]},"alphafold":{"accession":"Q16385","domains":[{"cath_id":"-","chopping":"20-72","consensus_level":"high","plddt":93.6568,"start":20,"end":72}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16385","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16385-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16385-F1-predicted_aligned_error_v6.png","plddt_mean":68.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SSX2","jax_strain_url":"https://www.jax.org/strain/search?query=SSX2"},"sequence":{"accession":"Q16385","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16385.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16385/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16385"}},"corpus_meta":[{"pmid":"7539744","id":"PMC_7539744","title":"Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7539744","citation_count":411,"is_preprint":false},{"pmid":"8840996","id":"PMC_8840996","title":"The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8840996","citation_count":193,"is_preprint":false},{"pmid":"7495284","id":"PMC_7495284","title":"Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript.","date":"1995","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7495284","citation_count":137,"is_preprint":false},{"pmid":"16849535","id":"PMC_16849535","title":"SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16849535","citation_count":94,"is_preprint":false},{"pmid":"17018603","id":"PMC_17018603","title":"The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018603","citation_count":81,"is_preprint":false},{"pmid":"26041735","id":"PMC_26041735","title":"PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26041735","citation_count":71,"is_preprint":false},{"pmid":"24457462","id":"PMC_24457462","title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24457462","citation_count":59,"is_preprint":false},{"pmid":"21996728","id":"PMC_21996728","title":"Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21996728","citation_count":57,"is_preprint":false},{"pmid":"16462762","id":"PMC_16462762","title":"The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16462762","citation_count":57,"is_preprint":false},{"pmid":"12007189","id":"PMC_12007189","title":"The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP.","date":"2002","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12007189","citation_count":54,"is_preprint":false},{"pmid":"17929270","id":"PMC_17929270","title":"Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17929270","citation_count":42,"is_preprint":false},{"pmid":"11422798","id":"PMC_11422798","title":"Primary synovial sarcoma of the kidney: Report of a case confirmed by molecular detection of the SYT-SSX2 fusion transcripts.","date":"2001","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/11422798","citation_count":39,"is_preprint":false},{"pmid":"25363656","id":"PMC_25363656","title":"Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25363656","citation_count":33,"is_preprint":false},{"pmid":"22797074","id":"PMC_22797074","title":"SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22797074","citation_count":33,"is_preprint":false},{"pmid":"12037676","id":"PMC_12037676","title":"Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12037676","citation_count":32,"is_preprint":false},{"pmid":"21904219","id":"PMC_21904219","title":"Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.","date":"2011","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/21904219","citation_count":32,"is_preprint":false},{"pmid":"22594313","id":"PMC_22594313","title":"Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.","date":"2012","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22594313","citation_count":31,"is_preprint":false},{"pmid":"26259251","id":"PMC_26259251","title":"β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26259251","citation_count":30,"is_preprint":false},{"pmid":"19337376","id":"PMC_19337376","title":"The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19337376","citation_count":26,"is_preprint":false},{"pmid":"12505262","id":"PMC_12505262","title":"Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma.","date":"2002","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12505262","citation_count":24,"is_preprint":false},{"pmid":"17686994","id":"PMC_17686994","title":"The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17686994","citation_count":24,"is_preprint":false},{"pmid":"11207827","id":"PMC_11207827","title":"Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcifications.","date":"2001","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11207827","citation_count":24,"is_preprint":false},{"pmid":"17509396","id":"PMC_17509396","title":"Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation.","date":"2007","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17509396","citation_count":21,"is_preprint":false},{"pmid":"24681846","id":"PMC_24681846","title":"Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24681846","citation_count":19,"is_preprint":false},{"pmid":"15382048","id":"PMC_15382048","title":"Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15382048","citation_count":19,"is_preprint":false},{"pmid":"25249625","id":"PMC_25249625","title":"SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25249625","citation_count":18,"is_preprint":false},{"pmid":"24645645","id":"PMC_24645645","title":"SSX2-4 expression in early-stage non-small cell lung cancer.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24645645","citation_count":17,"is_preprint":false},{"pmid":"25078248","id":"PMC_25078248","title":"Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.","date":"2014","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/25078248","citation_count":17,"is_preprint":false},{"pmid":"34729377","id":"PMC_34729377","title":"Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/34729377","citation_count":16,"is_preprint":false},{"pmid":"14677925","id":"PMC_14677925","title":"Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.","date":"2003","source":"Cancer immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14677925","citation_count":16,"is_preprint":false},{"pmid":"15153546","id":"PMC_15153546","title":"Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153546","citation_count":16,"is_preprint":false},{"pmid":"24492013","id":"PMC_24492013","title":"DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.","date":"2014","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/24492013","citation_count":15,"is_preprint":false},{"pmid":"15596411","id":"PMC_15596411","title":"Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15596411","citation_count":15,"is_preprint":false},{"pmid":"12469233","id":"PMC_12469233","title":"Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital.","date":"2002","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/12469233","citation_count":14,"is_preprint":false},{"pmid":"8773470","id":"PMC_8773470","title":"Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors.","date":"1996","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8773470","citation_count":14,"is_preprint":false},{"pmid":"22344619","id":"PMC_22344619","title":"Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22344619","citation_count":13,"is_preprint":false},{"pmid":"18992642","id":"PMC_18992642","title":"Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma.","date":"2008","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18992642","citation_count":13,"is_preprint":false},{"pmid":"22007079","id":"PMC_22007079","title":"Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript.","date":"2011","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22007079","citation_count":12,"is_preprint":false},{"pmid":"21630107","id":"PMC_21630107","title":"A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.","date":"2011","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/21630107","citation_count":12,"is_preprint":false},{"pmid":"34538011","id":"PMC_34538011","title":"Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel EWSR1-SSX2 fusion identified by RNA-based next-generation sequencing.","date":"2021","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34538011","citation_count":11,"is_preprint":false},{"pmid":"30005870","id":"PMC_30005870","title":"Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30005870","citation_count":10,"is_preprint":false},{"pmid":"30186454","id":"PMC_30186454","title":"Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30186454","citation_count":10,"is_preprint":false},{"pmid":"17931884","id":"PMC_17931884","title":"Expression and purification of the cancer antigen SSX2: a potential cancer vaccine.","date":"2007","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/17931884","citation_count":8,"is_preprint":false},{"pmid":"16682293","id":"PMC_16682293","title":"A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma.","date":"2006","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16682293","citation_count":8,"is_preprint":false},{"pmid":"12201571","id":"PMC_12201571","title":"A rare synovial sarcoma of the kidney exhibiting translocation (X;18) and SYT-SSX2 fusion gene.","date":"2002","source":"Zhonghua yi xue za zhi = Chinese medical journal; Free China ed","url":"https://pubmed.ncbi.nlm.nih.gov/12201571","citation_count":8,"is_preprint":false},{"pmid":"27276714","id":"PMC_27276714","title":"SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27276714","citation_count":8,"is_preprint":false},{"pmid":"12683902","id":"PMC_12683902","title":"SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome.","date":"2003","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12683902","citation_count":7,"is_preprint":false},{"pmid":"12521124","id":"PMC_12521124","title":"Expression of SSX-2 and SSX-4 genes in neuroblastoma.","date":"2002","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/12521124","citation_count":6,"is_preprint":false},{"pmid":"20830232","id":"PMC_20830232","title":"Primary pulmonary biphasic synovial sarcoma confirmed by molecular detection of a SYT-SSX2 fusion gene: report of 1 case.","date":"2010","source":"The Korean journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20830232","citation_count":5,"is_preprint":false},{"pmid":"15350633","id":"PMC_15350633","title":"Are there geographical differences in the frequency of SYT-SSX1 and SYT-SSX2 chimeric transcripts in synovial sarcoma?","date":"2004","source":"Cancer detection and prevention","url":"https://pubmed.ncbi.nlm.nih.gov/15350633","citation_count":5,"is_preprint":false},{"pmid":"19826807","id":"PMC_19826807","title":"Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal.","date":"2009","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19826807","citation_count":5,"is_preprint":false},{"pmid":"18626152","id":"PMC_18626152","title":"A t(X; 18) SYT-SSX2 positive synovial sarcoma in the pelvis of a young adult male: a rare case report with review of literature.","date":"2008","source":"Indian journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18626152","citation_count":5,"is_preprint":false},{"pmid":"23109999","id":"PMC_23109999","title":"Primary Monophasic Synovial Sarcoma Arising in the Mesentery: Case Report of an Extremely Rare Mesenteric Sarcoma Confirmed by Molecular Detection of a SYT-SSX2 Fusion Transcript.","date":"2012","source":"Korean journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23109999","citation_count":4,"is_preprint":false},{"pmid":"31695025","id":"PMC_31695025","title":"A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31695025","citation_count":4,"is_preprint":false},{"pmid":"32691176","id":"PMC_32691176","title":"Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review.","date":"2020","source":"Surgical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/32691176","citation_count":4,"is_preprint":false},{"pmid":"29325767","id":"PMC_29325767","title":"Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature.","date":"2018","source":"Journal of stomatology, oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/29325767","citation_count":3,"is_preprint":false},{"pmid":"22393780","id":"PMC_22393780","title":"[Analysis of SYT/SSX1 and SYT/SSX2 fusion genes from synovial sarcoma].","date":"2011","source":"Molekuliarnaia biologiia","url":"https://pubmed.ncbi.nlm.nih.gov/22393780","citation_count":2,"is_preprint":false},{"pmid":"34808373","id":"PMC_34808373","title":"SSX2 promotes the formation of a novel type of intranuclear lamin bodies.","date":"2021","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34808373","citation_count":1,"is_preprint":false},{"pmid":"15854347","id":"PMC_15854347","title":"[Expression of SSX2 gene in human urologic neoplasms].","date":"2005","source":"Zhonghua wai ke za zhi [Chinese journal of surgery]","url":"https://pubmed.ncbi.nlm.nih.gov/15854347","citation_count":0,"is_preprint":false},{"pmid":"41662627","id":"PMC_41662627","title":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","date":"2026","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/41662627","citation_count":0,"is_preprint":false},{"pmid":"16837900","id":"PMC_16837900","title":"Expression of SSX2 tumor antigen in baculovirus expression system and its application for screening of blood serum of melanoma patients.","date":"2006","source":"Experimental oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16837900","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29771,"output_tokens":4569,"usd":0.078924},"stage2":{"model":"claude-opus-4-6","input_tokens":8055,"output_tokens":2943,"usd":0.170775},"total_usd":0.249699,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain, identifying SSX2 as encoding a putative transcriptional repressor. The SYT-SSX2 fusion results from the t(X;18)(p11.2;q11.2) chromosomal translocation in synovial sarcoma.\",\n      \"method\": \"Sequence analysis of cloned fusion transcripts from synovial sarcoma specimens\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and sequence characterization, foundational paper with 411 citations\",\n      \"pmids\": [\"7539744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SSX2 interacts directly with two novel proteins: RAB3IP (human homologue of a Ras-like GTPase interactor) and SSX2IP (a novel nuclear protein). Both interactions occur via the N-terminal moiety of SSX2. Coexpression of SSX2 with RAB3IP relocates RAB3IP from the cytoplasm to the nucleus, and SSX2IP colocalizes with SSX2 in the nucleus.\",\n      \"method\": \"Yeast two-hybrid screen, GST pull-down assays (in vitro direct interaction), immunofluorescence of transfected cells, deletion mutant analysis\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal yeast two-hybrid plus GST pulldown reconstitution plus localization experiments with deletion mapping\",\n      \"pmids\": [\"12007189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with it, independent of canonical Wnt signaling. Depletion of SYT-SSX2 in primary synovial sarcoma cells results in loss of nuclear beta-catenin and decreased beta-catenin signaling activity.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, reporter assays, siRNA knockdown in primary synovial sarcoma cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, functional reporter assays, and loss-of-function in primary tumor cells with defined phenotypic readout\",\n      \"pmids\": [\"16462762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SYT-SSX1 interacts preferentially with the transcriptional repressor Snail, while SYT-SSX2 interacts preferentially with Slug. Both fusion proteins prevent their respective repressors from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription.\",\n      \"method\": \"Coimmunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, ChIP, and functional reporter assays provide multiple orthogonal methods\",\n      \"pmids\": [\"16849535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The SS18-SSX2 fusion protein functions as a transcriptional 'activator-repressor' that deregulates downstream target genes (including IGF2 and CD44) through epigenetic mechanisms, affecting histone modifications at CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region. SS18 moiety is associated with the SWI/SNF complex (coactivator) while SSX moiety is associated with the polycomb complex (corepressor), and both activities are retained in the fusion.\",\n      \"method\": \"Conditional expression system, cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal epigenomic methods (ChIP, bisulfite sequencing) with conditional expression system\",\n      \"pmids\": [\"17018603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SYT-SSX2 remodels the cytoskeleton by activating the Eph/ephrin signaling pathway, inducing cell elongation, neurite-like extensions, and cell repulsion. SYT-SSX2 also independently stabilizes the microtubule network through accumulation of detyrosinated Glu tubulin. Blockade of EphB2 signaling reverses the aberrant cytoskeletal phenotype.\",\n      \"method\": \"Retroviral transduction, immunofluorescence, EphB2 signaling blockade rescue experiments, western blotting for Glu tubulin, nocodazole resistance assay, immunohistochemistry of synovial sarcoma tissues\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including genetic rescue (EphB2 blockade), confirmed in primary tumor tissue\",\n      \"pmids\": [\"17686994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SYT-SSX2 interacts with the polycomb repressive complex and causes destabilization of the polycomb subunit Bmi1, resulting in impaired polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes.\",\n      \"method\": \"Co-immunoprecipitation, western blotting for H2A ubiquitination, RT-PCR for polycomb target gene reactivation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP with functional epigenetic readout (H2A ubiquitination) from a single lab\",\n      \"pmids\": [\"19337376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SYT-SSX2 reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells by directly occupying and activating neural-specific genes while suppressing normal myogenic and adipogenic differentiation programs. SYT-SSX2 directly targets and upregulates FGFR2, and FGFR2 knockdown abrogates growth and attenuates the neural phenotype of both mesenchymal stem cells and synovial sarcoma cells.\",\n      \"method\": \"Retroviral transduction, genome-wide ChIP analysis, siRNA knockdown of FGFR2, differentiation assays, gene expression profiling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based genome-wide occupancy, validated with loss-of-function rescue experiments in multiple cell types\",\n      \"pmids\": [\"21996728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SS18-SSX2 increases BCL2 expression but represses other anti-apoptotic genes MCL1 and BCL2A1 by directly suppressing their expression via binding through ATF2 to the CRE in the promoters of these genes and recruiting TLE1/Groucho corepressor.\",\n      \"method\": \"ChIP, promoter reporter assays, co-immunoprecipitation, siRNA knockdown, in vitro and in vivo pharmacological studies with ABT-263\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct promoter binding, reporter assays, and identification of corepressor (TLE1) recruitment\",\n      \"pmids\": [\"22797074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SYT-SSX2 is recruited genome-wide predominantly to polycomb-modified chromatin sites enriched with H3K27me3. Activated genes show SYT-SSX2/H3K27me3 sites within their body or near TSS, while downregulated genes are characterized by SYT-SSX2/H3K27me3 at long-range positions or by activation marks within the gene body.\",\n      \"method\": \"Genome-wide ChIP-seq, expression profiling, hierarchical clustering of epigenetic marks\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP-seq with integrated expression analysis providing mechanistic insight into recruitment\",\n      \"pmids\": [\"22594313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SSX2 is a chromatin-associated protein that binds double-stranded DNA in a sequence non-specific manner and antagonizes BMI1 and EZH2 polycomb group body formation, derepressing PcG target genes and negatively regulating H3K27me3 levels in melanoma cells. SSX2 antagonizes PcG function through an indirect mechanism without directly affecting overall PcG complex composition.\",\n      \"method\": \"Chromatin fractionation, DNA binding assays (EMSA/pulldown), immunofluorescence for PcG body formation, ChIP for H3K27me3, gene expression analysis after SSX2 knockdown/overexpression\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro DNA binding, ChIP, and functional gene derepression assays\",\n      \"pmids\": [\"25249625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ectopic SSX2 expression induces DNA damage, replication stress, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and a late apoptotic response in melanoma and breast cancer cells. Knockdown of SSX2 in melanoma cell lines reduces tumor cell growth, demonstrating SSX2 supports melanoma cell proliferation.\",\n      \"method\": \"Stable transfection/overexpression, flow cytometry for DNA content, immunofluorescence for γH2AX (DNA damage marker), β-galactosidase senescence assay, siRNA knockdown with proliferation assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple phenotypic readouts from single lab, overexpression and knockdown both performed\",\n      \"pmids\": [\"25363656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SSX2 knockdown in prostate cancer cells results in epithelial morphology, increased cell proliferation, increased expression of genes involved in focal adhesion, decreased anchorage-independent growth, increased invasion, and increased tumorigenicity in vivo, indicating SSX2 regulates focal adhesion-related processes rather than driving EMT.\",\n      \"method\": \"siRNA knockdown, overexpression, morphological analysis, gene expression profiling, invasion assays, in vivo tumorigenicity assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — knockdown and overexpression with defined cellular phenotypes and in vivo validation, single lab\",\n      \"pmids\": [\"27276714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Mediator complex is essential for SSX2-induced senescence; knockdown of MED1, MED4, and MED14 subunits perturbs SSX2-induced senescence development. This effect is specific to SSX2-induced senescence, as MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence.\",\n      \"method\": \"Functional genetic screen (RNAi library), siRNA validation knockdown experiments, β-galactosidase senescence assay, immunostaining of melanoma tumors vs. benign nevi, RNA-seq analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide genetic screen with validation experiments, specificity controls with other senescence inducers\",\n      \"pmids\": [\"31695025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SSX2 induces the formation of a novel type of intranuclear lamin bodies containing both A and B type lamins but no other nuclear lamina components. This effect is dependent on S-phase progression and is independent of known SSX2 interactions with polycomb proteins and the Mediator complex.\",\n      \"method\": \"Immunofluorescence in multiple breast epithelial cell line models, cell cycle synchronization experiments, co-immunoprecipitation to test polycomb/Mediator involvement\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, immunofluorescence-based localization with cell cycle dependency established, no direct biochemical reconstitution\",\n      \"pmids\": [\"34808373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SSX2 expression in prostate cancer cell lines can be induced by treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine, indicating that SSX2 expression is regulated by DNA methylation. Normal prostate epithelial cells do not show SSX2 induction under the same treatment.\",\n      \"method\": \"RT-PCR after 5-aza-2'-deoxycytidine treatment in cancer cell lines vs. normal cell line\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological demethylation experiment with appropriate normal cell control establishing epigenetic regulation\",\n      \"pmids\": [\"17929270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SSX2 contains a C-terminal nuclear localization signal (NLS) that is required for its nuclear targeting. When expressed in Pichia pastoris, SSX2 containing the NLS accumulates in the endoplasmic reticulum in misfolded form rather than translocating to the nucleus, whereas deletion of the NLS allows correct folding and secretion.\",\n      \"method\": \"Indirect immunofluorescence of SSX2 and NLS-deletion mutant expressed in yeast, secretion assays, protein folding analysis\",\n      \"journal\": \"Applied microbiology and biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — NLS function inferred from yeast expression system, not directly validated in mammalian cells\",\n      \"pmids\": [\"19826807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SSX2 overexpression in MCF-7 breast cancer cells suppresses ERα and E-cadherin expression, promotes cell invasion in vitro and in vivo, and differentially regulates a set of proteins identified by comparative proteomics.\",\n      \"method\": \"Stable transfection, MTT assay, flow cytometry, transwell invasion assay, in vivo tumorigenicity assay, 2D-gel comparative proteomics\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab overexpression study with phenotypic readouts but limited mechanistic pathway placement\",\n      \"pmids\": [\"22344619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RAB3IP interacts with SSX2 and co-expression of RAB3IP and SSX2 is correlated in gastric cancer; RAB3IP promotes an invasive phenotype and is associated with epithelial-mesenchymal transition markers.\",\n      \"method\": \"Co-immunoprecipitation, western blotting, invasion assays in gastric cancer cell lines, expression correlation analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP confirming prior yeast two-hybrid finding, phenotypic studies without direct mechanistic pathway placement for SSX2\",\n      \"pmids\": [\"30005870\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SSX2 is a nuclear chromatin-associated protein that binds double-stranded DNA non-specifically, functions as a transcriptional repressor through its KRAB-homology domain, antagonizes polycomb repressive complex activity (destabilizing Bmi1, reducing H3K27me3, and derepressing PcG target genes), and when fused to SYT (as SS18-SSX2) acts as an aberrant transcriptional activator-repressor that recruits beta-catenin to the nucleus, interacts with Slug to derepress E-cadherin, binds ATF2/TLE1 to repress MCL1/BCL2A1, activates ephrin/EphB2 signaling to remodel the cytoskeleton, and genome-wide targets H3K27me3-marked polycomb chromatin to reprogram mesenchymal stem cell gene expression networks toward neural lineage commitment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SSX2 is a nuclear chromatin-associated protein that functions as a transcriptional repressor and antagonist of polycomb group (PcG) repressive complexes. Its N-terminal KRAB-homology domain mediates transcriptional repression, while the full-length protein binds double-stranded DNA in a sequence-nonspecific manner, destabilizes PcG body formation (including Bmi1 and EZH2), reduces H3K27me3 levels, and derepresses PcG target genes [PMID:7539744, PMID:25249625]. SSX2 interacts with SSX2IP and RAB3IP through its N-terminal region, induces DNA damage and replication stress leading to Mediator-dependent cellular senescence, and promotes formation of intranuclear lamin bodies during S-phase [PMID:12007189, PMID:25363656, PMID:31695025, PMID:34808373]. When fused to SS18 via the t(X;18) translocation in synovial sarcoma, the SS18-SSX2 oncoprotein is recruited genome-wide to H3K27me3-marked polycomb chromatin, where it reprograms mesenchymal stem cell differentiation toward neural lineage by coupling SWI/SNF coactivator and PcG corepressor activities, recruits β-catenin to the nucleus, sequesters Slug to derepress E-cadherin, and activates Eph/ephrin signaling to remodel the cytoskeleton [PMID:22594313, PMID:21996728, PMID:16462762, PMID:16849535, PMID:17686994].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of SSX2 as a KRAB-domain-containing putative transcriptional repressor fused to SYT in the synovial sarcoma t(X;18) translocation established the gene's basic domain architecture and disease relevance.\",\n      \"evidence\": \"Cloning and sequence analysis of fusion transcripts from synovial sarcoma specimens\",\n      \"pmids\": [\"7539744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No direct evidence of transcriptional repression activity at this stage\", \"KRAB domain homology does not confirm functional equivalence to canonical KRAB repressors\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery of RAB3IP and SSX2IP as direct N-terminal interaction partners of SSX2, with SSX2 capable of relocalizing RAB3IP to the nucleus, revealed SSX2's capacity to remodel protein subcellular localization.\",\n      \"evidence\": \"Yeast two-hybrid screen, GST pull-down, immunofluorescence, deletion mapping in transfected cells\",\n      \"pmids\": [\"12007189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of RAB3IP nuclear relocalization unknown\", \"Endogenous complex formation not demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Multiple studies established that the SS18-SSX2 fusion protein functions as a dual activator-repressor by coupling SWI/SNF coactivation (SS18 moiety) with PcG corepression (SSX2 moiety), deregulating targets including IGF2 and CD44 through epigenetic mechanisms, while also recruiting β-catenin to the nucleus and sequestering Slug to derepress E-cadherin.\",\n      \"evidence\": \"Conditional expression with microarray profiling, ChIP for histone modifications, bisulfite sequencing, Co-IP, reporter assays, and siRNA knockdown in primary synovial sarcoma cells\",\n      \"pmids\": [\"17018603\", \"16462762\", \"16849535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SSX2 moiety directly engages PcG complexes biochemically was not resolved\", \"Whether β-catenin and Slug interactions are direct or mediated through SS18 was unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"SS18-SSX2 was shown to activate Eph/ephrin signaling to remodel the cytoskeleton and stabilize microtubules, and separately SSX2 expression was found to be silenced by DNA methylation in normal tissues.\",\n      \"evidence\": \"EphB2 signaling blockade rescue experiments with immunofluorescence and nocodazole resistance; RT-PCR after 5-aza-2'-deoxycytidine treatment\",\n      \"pmids\": [\"17686994\", \"17929270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional target linking SS18-SSX2 to EphB2 upregulation not identified\", \"Methylation-based silencing not mapped to specific CpG islands\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The SSX2 portion of SS18-SSX2 was shown to destabilize the PcG subunit Bmi1 and impair H2A ubiquitination, providing a mechanism for PcG target gene reactivation, while a C-terminal NLS was identified as necessary for nuclear targeting.\",\n      \"evidence\": \"Co-IP, H2A ubiquitination western blotting, RT-PCR for PcG target reactivation; NLS deletion mutant analysis in yeast\",\n      \"pmids\": [\"19337376\", \"19826807\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Bmi1 destabilization mechanism (proteasomal vs. transcriptional) not defined\", \"NLS function validated only in yeast, not mammalian cells\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genome-wide ChIP analysis revealed that SS18-SSX2 directly occupies and activates neural-specific genes while suppressing myogenic programs in mesenchymal stem cells, with FGFR2 identified as a critical direct target whose knockdown abrogates sarcoma cell growth.\",\n      \"evidence\": \"Genome-wide ChIP, retroviral transduction of mesenchymal stem cells, FGFR2 siRNA knockdown with differentiation and growth assays\",\n      \"pmids\": [\"21996728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FGFR2 activation is sufficient for lineage reprogramming not tested\", \"Cell-of-origin for synovial sarcoma in vivo not established by this study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"ChIP-seq demonstrated that SS18-SSX2 is recruited genome-wide to H3K27me3-marked polycomb chromatin, with gene activation correlating to proximal occupancy and repression to distal occupancy or ATF2/TLE1 corepressor recruitment at specific promoters (MCL1, BCL2A1).\",\n      \"evidence\": \"Genome-wide ChIP-seq with integrated expression profiling; ChIP and reporter assays at MCL1/BCL2A1 promoters with TLE1 Co-IP\",\n      \"pmids\": [\"22594313\", \"22797074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SS18-SSX2 directly contacts H3K27me3 or is recruited via adaptor proteins remains unresolved\", \"Structural basis of ATF2/TLE1 interaction not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Wild-type SSX2 was established as a chromatin-associated, sequence-nonspecific DNA-binding protein that antagonizes PcG body formation and H3K27me3 levels through an indirect mechanism, and whose ectopic expression induces DNA damage, replication stress, and p53-dependent senescence.\",\n      \"evidence\": \"EMSA/DNA pulldown, ChIP for H3K27me3, immunofluorescence for PcG bodies; flow cytometry, γH2AX immunofluorescence, β-galactosidase senescence assay with knockdown controls\",\n      \"pmids\": [\"25249625\", \"25363656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which SSX2 disrupts PcG bodies without altering complex composition is unknown\", \"Whether DNA damage is a direct consequence of chromatin binding or an indirect effect not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A functional genetic screen identified the Mediator complex (MED1, MED4, MED14) as specifically required for SSX2-induced senescence, distinguishing SSX2's senescence pathway from oncogene- or drug-induced senescence.\",\n      \"evidence\": \"RNAi library screen with siRNA validation, specificity controls against B-Raf and Epirubicin senescence, RNA-seq\",\n      \"pmids\": [\"31695025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SSX2 directly contacts Mediator subunits or acts through transcriptional intermediaries unknown\", \"How Mediator engagement relates to PcG antagonism not clarified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SSX2 was found to induce novel intranuclear lamin A/B bodies in an S-phase-dependent manner, independent of its known PcG and Mediator interactions, revealing a previously unrecognized effect on nuclear architecture.\",\n      \"evidence\": \"Immunofluorescence in breast epithelial cell lines, cell cycle synchronization, Co-IP to exclude PcG/Mediator involvement\",\n      \"pmids\": [\"34808373\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of lamin body formation not determined\", \"Whether lamin body formation is linked to DNA damage or replication stress phenotypes not tested\", \"Biochemical reconstitution of SSX2-lamin interaction not performed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanism by which SSX2 disrupts PcG body formation without altering complex composition, the structural basis of its sequence-nonspecific DNA binding, and how its chromatin remodeling, Mediator-dependent senescence, and lamin body formation activities are integrated remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of SSX2 bound to DNA or chromatin\", \"No reconstituted system defining minimal domains for PcG antagonism\", \"Relationship between lamin body formation, replication stress, and senescence unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 10, 14, 16]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 6, 9, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 7, 8]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SSX2IP\",\n      \"RAB3IP\",\n      \"BMI1\",\n      \"CTNNB1\",\n      \"SNAI2\",\n      \"ATF2\",\n      \"TLE1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}